Your browser doesn't support javascript.
loading
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu, Lillian L; Even, Caroline; Mesía, Ricard; Remenar, Eva; Daste, Amaury; Delord, Jean-Pierre; Krauss, Jürgen; Saba, Nabil F; Nabell, Lisle; Ready, Neal E; Braña, Irene; Kotecki, Nuria; Zandberg, Dan P; Gilbert, Jill; Mehanna, Hisham; Bonomi, Marcelo; Jarkowski, Anthony; Melillo, Giovanni; Armstrong, Jon M; Wildsmith, Sophie; Fayette, Jérôme.
Affiliation
  • Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • Even C; Department of Head and Neck Cancer, Gustave Roussy, Villejuif, France.
  • Mesía R; Medical Oncology Department, Catalan Institute of Oncology-Badalona, University of Barcelona, IDIBELL, Barcelona, Spain.
  • Remenar E; Fej-nyak Állcsont, Rekonstrukciós Plasztikai Sebészeti és Laser Sebészeti Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
  • Daste A; Department of Medical Oncology, Hôpital Saint André, Bordeaux, France.
  • Delord JP; Département d'Oncologie Médicale, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
  • Krauss J; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.
  • Saba NF; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
  • Nabell L; Department of Medical Oncology, University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham.
  • Ready NE; Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Braña I; Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Spain.
  • Kotecki N; Département de Cancérologie Cervico-Faciale, Centre de Lutte Contre le Cancer-Centre Oscar Lambret, Lille, France.
  • Zandberg DP; University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Gilbert J; Department of Hematology and Oncology, Henry-Joyce Cancer Clinic, Nashville, Tennessee.
  • Mehanna H; Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, United Kingdom.
  • Bonomi M; Department of Medical Oncology, The Ohio State University, Columbus, Ohio.
  • Jarkowski A; AstraZeneca, Gaithersburg, Maryland.
  • Melillo G; Now with Bristol-Myers Squibb, New Brunswick, New Jersey.
  • Armstrong JM; AstraZeneca, Gaithersburg, Maryland.
  • Wildsmith S; AstraZeneca, Cambridge, United Kingdom.
  • Fayette J; Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
JAMA Oncol ; 5(2): 195-203, 2019 02 01.
Article in En | MEDLINE | ID: mdl-30383184
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Antibodies, Monoclonal, Humanized / B7-H1 Antigen / Antineoplastic Agents, Immunological / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Asia / Europa Language: En Journal: JAMA Oncol Year: 2019 Type: Article Affiliation country: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Antibodies, Monoclonal, Humanized / B7-H1 Antigen / Antineoplastic Agents, Immunological / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Asia / Europa Language: En Journal: JAMA Oncol Year: 2019 Type: Article Affiliation country: Canada